Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

The capabilities of cytochrome P4503A4 (CYP3A4), CYP3A5, and fetal hepatic microsomes containing CYP3A7 to metabolize midazolam were investigated using human hepatic microsomes and purified CYP3A4 and CYP3A5. Under initial rate conditions and high substrate concentration (400 microM midazolam), variability among eighteen human liver microsomal samples was 30- and 16- fold for 1'- and 4-hydroxylation of midazolam, respectively. Exclusion of two samples isolated from patients previously administered barbiturates reduced the inter-individual variability to 10.5- and 6.0-fold for 1'- and 4-hydroxylation, respectively. Six fetal hepatic microsomal samples showed 10-fold variation in both 1'-hydroxymidazolam and 4-hydroxymidazolam formation rates. The rates of formation of 4-hydroxymidazolam and 1'-hydroxymidazolam from midazolam by adult samples containing only CYP3A4 and by fetal liver samples were highly correlated (r2 = 0.99 and 0.97, P < 0.01, respectively). The rates of formation of 1'-hydroxymidazolam and 4-hydroxymidazolam from midazolam (400 microM) by adult samples that contained only CYP3A4 were correlated significantly (P < 0.01) with the ability of the samples to N-demethylate erythromycin (r2 = 0.95 and 0.92, respectively). 6 beta-hydroxylate testosterone (r2 = 0.96 and 0.96, respectively), and the CYP3A4 content of the samples (r2 = 0.89 and 0.86, respectively). Microsomal samples containing CYP3A5 in addition to CYP3A4 exhibited a significantly greater ratio of 1'-hydroxymidazolam to 4-hydroxymidazolam compared with samples containing only CYP3A4 or CYP3A7 (P < 0.001). Purified CYP3A5 in a reconstituted system, consisting of dilauroylphosphatidylcholine, cytochrome b5, and NADPH-cytochrome P450 reductase, and an NADPH-regenerating system displayed a 2-fold greater rate of 1'-hydroxymidazolam formation and a similar rate of 4-hydroxymidazolam formation compared with a reconstituted system with CYP3A4. In conclusion, CYP3A4, CYP3A5, and fetal microsomes containing CYP3A7 catalyze 1'- and 4-hydroxylation of midazolam with the ratio of these metabolites indicative of the CYP3A form.

[1]  B. Kahan,et al.  Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. , 1988, Transplantation.

[2]  B. Ring,et al.  In vitro methods for assessing human hepatic drug metabolism: their use in drug development. , 1993, Drug metabolism reviews.

[3]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[4]  A. Hall,et al.  Identification of distinct cytoplasmic targets for ras/R-ras and rho regulatory proteins. , 1989, The Journal of biological chemistry.

[5]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[6]  A. Rane,et al.  Human fetal and adult liver metabolism of ethylmorphine. Relation to immunodetected cytochrome P-450 PCN and interactions with important fetal corticosteroids. , 1989, Biochemical pharmacology.

[7]  van der Hoeven Ta,et al.  Preparation and Properties of Partially Purified Cytochrome P-450 and Reduced Nicotinamide Adenine Dinucleotide Phosphate-Cytochrome P-450 Reductase from Rabbit Liver Microsomes , 1974 .

[8]  C. Puglisi,et al.  Determination of midazolam (Versed) and its metabolites in plasma by high-performance liquid chromatography. , 1985, Journal of chromatography.

[9]  M. Sari,et al.  Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. , 1990, Biochemistry.

[10]  R. Rahmani,et al.  Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. , 1988, Biochemical Pharmacology.

[11]  F. Guengerich,et al.  Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[12]  Kenneth J. Fishman,et al.  Comparison of urinary 6‐β‐cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity , 1992, Clinical pharmacology and therapeutics.

[13]  T. Kamataki,et al.  P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. , 1987, The Journal of biological chemistry.

[14]  M. Eckert,et al.  Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. , 1983, British journal of clinical pharmacology.

[15]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[16]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[17]  F. Guengerich,et al.  Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.

[18]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[19]  T. Kamataki,et al.  Stable expression of cytochrome P450IIIA7 cDNA in human breast cancer cell line MCF-7 and its application to cytotoxicity testing. , 1992, Archives of biochemistry and biophysics.

[20]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[21]  P. Watkins,et al.  Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.

[22]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[23]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[24]  D. Breimer,et al.  Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. , 1988, Biochemical pharmacology.

[25]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Watkins,et al.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. , 1989, The Journal of clinical investigation.

[27]  Y. Horsmans,et al.  Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6 beta-hydroxycortisol in 102 healthy subjects on rifampicin. , 1992, Pharmacology & toxicology.

[28]  J. Cano,et al.  Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. , 1988, Biochemical pharmacology.

[29]  T. Bienvenu,et al.  A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. , 1991, International journal of clinical pharmacology, therapy, and toxicology.

[30]  M. Danhof,et al.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. , 1984, Biochemical pharmacology.

[31]  C. Bonfils,et al.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[32]  Meindert Danhof,et al.  Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.

[33]  A. Rane,et al.  Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. , 1991, British journal of clinical pharmacology.

[34]  P. Watkins,et al.  The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease , 1992, Clinical pharmacology and therapeutics.

[35]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.

[36]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[37]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[38]  P. Watkins,et al.  Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. , 1985, Biochemistry.

[39]  D. Waxman.  Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmentally induced steroid 16 alpha-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. , 1984, The Journal of biological chemistry.